Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Austin Shandley

Physician Assistant Kansas City, MO Physician Assistant

NPI 1881085066 CMS profile 10700154

8656 N Ambassador Dr, Kansas City, MO 64154

Open in the dashboard

General payments

$11,085

430 records reported · program years 2021–2025

Research payments

$1,396

Paid to them · 8 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Austin Shandley of Kansas City, MO is reported in the CMS Open Payments database as having received $11,085 across 430 general payments and $1,396 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,238 113
2024 General $2,284 72
2024 Research $1,396 8
2023 General $2,416 85
2022 General $1,901 97
2021 General $1,245 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Austin Shandley
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Austin Shandley were reported at $3,238. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Austin Shandley Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,245 $132 $37–$438 $132
2022 $1,901 $155 $48–$522 $149
2023 $2,416 $167 $52–$557 $160
2024 $2,284 $178 $55–$600 $164
2025 $3,238 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $3,020 56 payments
  2. AbbVie, Inc. $973 66 payments
  3. UCB, Inc. $750 30 payments
  4. Sun Pharmaceutical Industries Inc. $742 41 payments
  5. E.R. Squibb & Sons, L.L.C. $710 45 payments
  6. Genzyme Corporation $692 22 payments
  7. Lilly USA, LLC $646 34 payments
  8. Novartis Pharmaceuticals Corporation $645 27 payments
  9. Amgen Inc. $588 29 payments
  10. Regeneron Healthcare Solutions, Inc. $434 16 payments
  11. Other $1,885 64 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,419 417 payments
  2. Consulting Fee $1,950 3 payments
  3. Education $680 9 payments
  4. Travel and Lodging $36 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $2,899 46 payments
  2. DUPIXENT Immunology $765 24 payments
  3. SOTYKTU $729 42 payments
  4. Bimzelx $609 22 payments
  5. Otezla $588 29 payments
  6. TALTZ $452 28 payments
  7. SKYRIZI $419 30 payments
  8. Klisyri $300 1 payment
  9. DUPIXENT Inflammation And Immunology $294 10 payments
  10. BLU-U $276 15 payments
  11. Other $4,146 248 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Sanofi US Services Inc. $1,396 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

868

Median for Physician Assistant: 241

Drug cost

$557,290

Median for Physician Assistant: $4,110

Branded share of claims

9.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tremfya Guselkumab Brand 21 $285,196
Otezla Apremilast Brand 23 $117,788
Humira(Cf) Pen Adalimumab Brand 12 $80,028
Dupixent Pen Dupilumab Brand 16 $61,539
Clobetasol Propionate Generic 67 $2,908
Ketoconazole Generic 92 $2,185
Triamcinolone Acetonide Generic 138 $1,374
Doxycycline Hyclate Generic 62 $1,195
Mometasone Furoate Generic 47 $871
Clindamycin Phosphate Generic 15 $628

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$192,365

Of which drugs: $27,648

Medicare patients

961

Average age 76

Services billed

4,453

356 women, 605 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 39%
Ischemic heart disease 32%
Diabetes 28%
Atrial fibrillation 22%
Chronic kidney disease 21%
COPD 17%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $1,072
  • Janssen Pharmaceuticals, Inc $34
$1,106 21 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $227
  • Celgene Corporation $40
$267 — —
DUPIXENT
  • SANOFI-AVENTIS U.S. LLC $99
  • GENZYME CORPORATION $66
  • Regeneron Healthcare Solutions, Inc. $38
$202 16 —
Otezla
  • Amgen Inc. $130
$130 23 —
SKYRIZI
  • AbbVie, Inc. $106
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

438 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record